AstraZeneca PLC Financials
| AZN Stock | 11,708 256.00 2.14% |
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Operating Income | 5.2 B | 10 B |
|
|
AstraZeneca | Select Account or Indicator |
Understanding current and past AstraZeneca PLC Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of AstraZeneca PLC's financial statements are interrelated, with each one affecting the others. For example, an increase in AstraZeneca PLC's assets may result in an increase in income on the income statement.
Please note, the presentation of AstraZeneca PLC's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, AstraZeneca PLC's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of AstraZeneca PLC's management manipulating its earnings.
AstraZeneca PLC Stock Summary
AstraZeneca PLC competes with Caledonia MiningPlc, Verizon Communications, Southwest Airlines, Mobile Tornado, and Pan American. AstraZeneca PLC is entity of United Kingdom. It is traded as Stock on LSE exchange.| Foreign Associates | |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Instrument | UK Stock View All |
| Exchange | London Exchange |
| ISIN | GB0009895292 |
| Business Address | 1 Francis Crick |
| Sector | Pharmaceuticals |
| Industry | Health Care |
| Benchmark | Dow Jones Industrial |
| Website | www.astrazeneca.com |
| Phone | 44 20 3749 5000 |
You should never invest in AstraZeneca PLC without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of AstraZeneca Stock, because this is throwing your money away. Analyzing the key information contained in AstraZeneca PLC's financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.
AstraZeneca PLC Key Financial Ratios
There are many critical financial ratios that AstraZeneca PLC's investors are exposed to on a daily basis, but they are usually grouped into few meaningful categories from each financial statement that AstraZeneca PLC reports annually and quarterly.| Revenue | 54.07 B | ||||
| Gross Profit | 44.44 B | ||||
| EBITDA | 17.12 B | ||||
| Net Income | 8.69 B | ||||
| Total Asset | 104.03 B |
AstraZeneca PLC Key Balance Sheet Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Total Assets | 66.7B | 105.4B | 96.5B | 101.1B | 104.0B | 109.2B | |
| Other Current Liab | 14.4B | 16.0B | 16.3B | 19.8B | 1.5B | 1.4B | |
| Net Debt | 12.5B | 24.5B | 23.1B | 22.8B | 24.6B | 25.9B | |
| Retained Earnings | 5.3B | 1.7B | (574M) | 4.5B | 3.2B | 3.0B | |
| Accounts Payable | 2.4B | 2.8B | 2.6B | 3.3B | 22.5B | 23.6B | |
| Cash | 7.8B | 6.3B | 6.2B | 5.8B | 5.5B | 4.7B | |
| Net Receivables | 3.8B | 6.0B | 7.2B | 8.4B | 13.0B | 13.6B | |
| Inventory | 4.0B | 9.0B | 4.7B | 5.4B | 5.3B | 2.8B | |
| Other Current Assets | 3.7B | 4.8B | 4.4B | 5.4B | 14.9B | 15.6B | |
| Total Liab | 51.1B | 66.1B | 59.4B | 62.0B | 63.2B | 66.3B | |
| Total Current Assets | 19.5B | 26.2B | 22.6B | 25.1B | 25.8B | 15.7B | |
| Short Term Debt | 2.4B | 2.9B | 6.5B | 5.4B | 2.5B | 1.6B | |
| Other Assets | 3.5B | 4.3B | 5.3B | 4.2B | 4.8B | 5.0B | |
| Intangible Assets | 20.9B | 42.4B | 39.3B | 38.1B | 37.2B | 39.0B | |
| Other Liab | 10.3B | 10.5B | 13.0B | 8.5B | 9.8B | 6.7B | |
| Long Term Debt | 17.5B | 28.1B | 23.0B | 22.4B | 26.5B | 27.8B | |
| Good Will | 11.8B | 20.0B | 19.8B | 20.0B | 21.0B | 22.1B | |
| Net Tangible Assets | (19.4B) | (17.2B) | (23.1B) | (22.1B) | (19.9B) | (20.9B) | |
| Short Long Term Debt | 2.2B | 1.7B | 5.3B | 5.1B | 2.2B | 2.5B |
AstraZeneca PLC Key Income Statement Accounts
An income statement is very similar to a cash flow statement, but instead of showing net revenue minus expenses, it only includes earnings before interest and taxes (EBIT). This number does not have all of the same line items that are on a cash flow statement, but it leaves out non-cash expenses like depreciation and amortization. For example, if you bought $100 worth of goods from Walmart (WMT) using your debit card that has an interest rate of 20%, then paid off the balance at the end of the month with a credit card that charges 30% interest, you would have an income statement showing EBIT of $80 because your expenses are lower than the amount that went into your pocket.
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Interest Expense | 1.3B | 1.3B | 1.3B | 1.6B | 1.7B | 1.8B | |
| Total Revenue | 26.6B | 37.4B | 44.4B | 45.8B | 54.1B | 56.8B | |
| Gross Profit | 21.3B | 25.0B | 32.0B | 37.8B | 43.9B | 46.1B | |
| Operating Income | 5.2B | 1.1B | 3.8B | 8.2B | 10.0B | 5.2B | |
| Ebit | 5.2B | 1.0B | 3.8B | 9.0B | 10.4B | 5.3B | |
| Research Development | 6.0B | 9.7B | 9.8B | 10.9B | 13.6B | 14.3B | |
| Ebitda | 8.1B | 5.1B | 9.1B | 13.9B | 17.1B | 18.0B | |
| Income Before Tax | 3.9B | (265M) | 2.5B | 6.9B | 8.7B | 4.6B | |
| Net Income | 3.2B | 112M | 3.3B | 6.0B | 7.0B | 3.6B | |
| Income Tax Expense | 772M | (380M) | (792M) | 938M | 1.7B | 1.7B | |
| Cost Of Revenue | 5.3B | 12.4B | 12.4B | 8.0B | 10.2B | 6.7B | |
| Minority Interest | 16M | (3M) | (5M) | (6M) | (6.9M) | (6.6M) | |
| Tax Provision | 772M | (380M) | (792M) | 938M | 1.7B | 1.7B | |
| Net Interest Income | (1.2B) | (1.3B) | (1.3B) | (1.3B) | (1.3B) | (1.3B) |
AstraZeneca PLC Key Cash Accounts
Cash flow analysis captures how much money flows into and out of AstraZeneca PLC. It measures of how well AstraZeneca is doing because it can show the actual money that comes into and out of the Company from sales instead of measuring expenses against revenue to determine earnings. You have to read the cash flow statement in three sections. The first section shows how much money AstraZeneca PLC brought in, usually known as net revenue or sales. This is different from earnings because it does not include expenses when determining net revenue for use on this part of the cash flow statement. Next, are operating activities, which show how much money AstraZeneca had leftover after paying for its expenses. This number can be calculated in two ways: by subtracting the total of all operating expenses from net revenue or by adding up changes to cash and other assets or liabilities on this part of the statement. The third section is about investing activities, which shows what AstraZeneca PLC has done with the money that it received from the sale of assets or what it spent to acquire new ones. This section can be broken down into two parts: investing in existing businesses (in other words, buying more stock) and investing in non-business activities like paying off debt or making acquisitions.
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Change To Inventory | (621M) | 1.6B | 3.9B | (669M) | (769.4M) | (730.9M) | |
| Change In Cash | 2.3B | (1.5B) | (55M) | (346M) | (208M) | (218.4M) | |
| Free Cash Flow | 2.2B | 3.8B | 7.2B | 6.6B | 7.3B | 7.6B | |
| Depreciation | 3.1B | 6.5B | 5.5B | 4.9B | 6.7B | 7.0B | |
| Other Non Cash Items | (2.6B) | (2.3B) | (1.9B) | (2.4B) | (2.6B) | (2.8B) | |
| Capital Expenditures | 2.6B | 2.2B | 2.6B | 3.8B | 4.6B | 4.8B | |
| Net Income | 3.9B | (265M) | 2.5B | 6.9B | 8.7B | 4.6B | |
| End Period Cash Flow | 7.5B | 6.0B | 6.0B | 5.6B | 5.4B | 4.2B | |
| Dividends Paid | 3.6B | 3.9B | 4.4B | 4.5B | 4.6B | 3.5B | |
| Investments | 2.0B | 605M | (3.0B) | (4.1B) | (8.0B) | (7.6B) | |
| Net Borrowings | (1.7B) | 1.4B | 7.7B | (1.4B) | (1.3B) | (1.2B) | |
| Change To Netincome | (816M) | (1.7B) | (615M) | (2.5B) | (2.2B) | (2.4B) |
AstraZeneca Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining AstraZeneca PLC's current stock value. Our valuation model uses many indicators to compare AstraZeneca PLC value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across AstraZeneca PLC competition to find correlations between indicators driving AstraZeneca PLC's intrinsic value. More Info.AstraZeneca PLC is number one stock in return on equity category among its peers. It also is number one stock in return on asset category among its peers reporting about 0.43 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for AstraZeneca PLC is roughly 2.33 . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the AstraZeneca PLC's earnings, one of the primary drivers of an investment's value.AstraZeneca PLC Systematic Risk
AstraZeneca PLC's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. AstraZeneca PLC volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was twenty with a total number of output elements of fourty-one. The Beta measures systematic risk based on how returns on AstraZeneca PLC correlated with the market. If Beta is less than 0 AstraZeneca PLC generally moves in the opposite direction as compared to the market. If AstraZeneca PLC Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one AstraZeneca PLC is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of AstraZeneca PLC is generally in the same direction as the market. If Beta > 1 AstraZeneca PLC moves generally in the same direction as, but more than the movement of the benchmark.
AstraZeneca PLC Total Assets Over Time
AstraZeneca PLC February 16, 2025 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of AstraZeneca PLC help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of AstraZeneca PLC. We use our internally-developed statistical techniques to arrive at the intrinsic value of AstraZeneca PLC based on widely used predictive technical indicators. In general, we focus on analyzing AstraZeneca Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build AstraZeneca PLC's daily price indicators and compare them against related drivers.
| Downside Deviation | 1.42 | |||
| Information Ratio | 0.1642 | |||
| Maximum Drawdown | 7.51 | |||
| Value At Risk | (2.14) | |||
| Potential Upside | 2.24 |
Complementary Tools for AstraZeneca Stock analysis
When running AstraZeneca PLC's price analysis, check to measure AstraZeneca PLC's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy AstraZeneca PLC is operating at the current time. Most of AstraZeneca PLC's value examination focuses on studying past and present price action to predict the probability of AstraZeneca PLC's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move AstraZeneca PLC's price. Additionally, you may evaluate how the addition of AstraZeneca PLC to your portfolios can decrease your overall portfolio volatility.
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings |